NCT05605522: A Study of [225Ac]-FPI-2059 in Adult Participants With Solid Tumours |
|
|
| Active, not recruiting | 1 | 42 | US, RoW | [225]-FPI-2059, [111In]-FPI-2058 | Fusion Pharmaceuticals Inc. | Pancreatic Ductal Adenocarcinoma (PDAC), Squamous Cell Carcinoma of Head and Neck, Colorectal Cancer, Gastric Cancer, Ewing Sarcoma, NTSR1 Expressing Solid Tumours, Neuroendocrine Differentiated (NED) Prostate Cancer | 06/25 | 09/25 | | |
